Genentech GO30140 (Hepatocellular Carcinoma) - Clinical Trial
What is the Purpose of this Study?
Who Can Participate in the Study?
- Have advanced or metastatic and/or unresectable hepatocellular carcinoma
What is Involved?
If you choose to join this study, you will:
- Receive either atezolizumab or atezolizumab and bevacizumab every 3 weeks through a vein in your arm
-- Continue to receive the study drug as long as your doctor thinks it is safe